Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis

Patients infected with hepatitis C virus (HCV) treated with interferon‐free direct‐acting antivirals may still require ribavirin. However, ribavirin is associated with adverse events that can limit its use. This open‐label, multicentre, Phase 3 study evaluated the safety and efficacy of ombitasvir/p...

Descripción completa

Detalles Bibliográficos
Autores principales: Poordad, Fred, Sedghi, Shahriar, Pockros, Paul J., Ravendhran, Natarajan, Reindollar, Robert, Lucey, Michael R., Epstein, Michael, Bank, Leslie, Bernstein, David, Trinh, Roger, Krishnan, Preethi, Polepally, Akshanth R., Unnebrink, Kristina, Martinez, Marisol, Nelson, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850388/
https://www.ncbi.nlm.nih.gov/pubmed/30980576
http://dx.doi.org/10.1111/jvh.13109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850388/
https://www.ncbi.nlm.nih.gov/pubmed/30980576
http://dx.doi.org/10.1111/jvh.13109

Ejemplares similares